Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 254

The DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.

IFN-γ: A cytokine at the right time, is in the right place

Open access
Burke, J. Daniel, Young, Howard A.·2019·Seminars in Immunology

Abstract

Interferon gamma has long been studied as a critical mediator of tumor immunity. In recent years, the complexity of cellular interactions that take place in the tumor microenvironment has become better appreciated in the context of immunotherapy. While checkpoint inhibitors have dramatically improved remission rates in cancer treatment, IFN-γ and related effectors continue to be identified as strong predictors of treatment success. In this review, we provide an overview of the multiple immunosuppressive barriers that IFN-γ has to overcome to eliminate tumors, and potential avenues for modulating the immune response in favor of tumor rejection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.smim.2019.05.002

Cites

194 of 194 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 194 references

Research works printed but not linked: 9

  1. Langer, 1994, Radiation inactivation of human gamma-interferon: cellular activation requires two dimers, Proc. Natl. Acad. Sci. U. S. A., 91, 5818, 10.1073/pnas.91.13.5818 · doi:10.1073/pnas.91.13.5818
  2. Yamashita, 1997, Nitric oxide is an effector molecule in inhibition of tumor cell growth by rIFN-gamma-activated rat neutrophils, Int. J. Cancer, 71, 223, 10.1002/(SICI)1097-0215(19970410)71:2<223::AID-IJC17>3.0.CO;2-I · doi:10.1002/(sici)1097-0215(19970410)71:2<223::aid-ijc17>3.0.co;2-i
  3. Hesse, 1984, Decreased T lymphocyte migration in patients with malignancy mediated by a suppressor cell population, J. Clin. Invest., 73, 1078, 10.1172/JCI111293 · doi:10.1172/jci111293
  4. Whittaker, 1971, Depressed lymphocyte function in carcinoma of the breast, Br. J. Surg., 58, 717, 10.1002/bjs.1800581002 · doi:10.1002/bjs.1800581002
  5. McCluskey, 1983, T lymphocyte subsets in the peripheral blood of patients with benign and malignant breast disease, Br. J. Cancer, 47, 307, 10.1038/bjc.1983.41 · doi:10.1038/bjc.1983.41
  6. Kawamura, 1995, Comparative analysis of B7-1 and B7-2 expression in Langerhans cells: differential regulation by T helper type 1 and T helper type 2 cytokines, Eur. J. Immunol., 25, 1913, 10.1002/eji.1830250718 · doi:10.1002/eji.1830250718
  7. Joss, 2000, IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway, Eur. J. Immunol., 30, 1683, 10.1002/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A · doi:10.1002/1521-4141(200006)30:6<1683::aid-immu1683>3.0.co;2-a
  8. Cohen, 1995, IL-12 deaths: explanation and a puzzle, Science, 270, 908, 10.1126/science.270.5238.908.a · doi:10.1126/science.270.5238.908.a · Paper page
  9. Cha, 2012, Plasmid IL-12 electroporation in melanoma, Hum. Vaccin. Immunother., 8, 1734, 10.4161/hv.22573 · doi:10.4161/hv.22573

Cited by

See all 254

Metadata

Authors
Burke, J. D., & Young, H. A.
Venue
Seminars in Immunology
Publisher
Elsevier BV
Published
2019-06
Volume
43
Pages
101280
ISSN
1044-5323 (ISSN-L)
OpenAlex
W2951756816
Cited by
254
References
194
FWCI
6.26
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IFN-γ: A cytokine at the right time, is in the right place. https://app.cochat.ai/papers/10.1016/j.smim.2019.05.002
The paper
Burke, J. D., & Young, H. A. (2019). IFN-γ: A cytokine at the right time, is in the right place. Seminars in Immunology. https://doi.org/10.1016/j.smim.2019.05.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.